Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2015-09, Vol.16 (5), p.e101-e104
Main Authors: Jenkins, Russell W, Oxnard, Geoffrey R, Elkin, Sheryl, Sullivan, E. Kelly, Carter, Jennifer L, Barbie, David A
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adenocarcinoma of Lung
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Crizotinib
Hematology, Oncology and Palliative Medicine
Humans
Lung adenocarcinoma
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
MET
Mutation
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins c-met - genetics
Pulmonary/Respiratory
Pyrazoles - therapeutic use
Pyridines - therapeutic use
RNA Splice Sites
Splice site mutation
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2015.01.009